Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-03-30
2010-11-09
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S410000, C546S062000, C546S061000, C548S421000, C548S423000
Reexamination Certificate
active
07829576
ABSTRACT:
This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.
REFERENCES:
patent: 4977158 (1990-12-01), Wieringa
patent: 6465458 (2002-10-01), Wong et al.
patent: 6610690 (2003-08-01), Wong et al.
patent: 6642235 (2003-11-01), Wong et al.
patent: 6703389 (2004-03-01), Wong et al.
patent: 6987107 (2006-01-01), Wong et al.
patent: 7241762 (2007-07-01), Wong et al.
patent: 7276503 (2007-10-01), Wong et al.
patent: 7317011 (2008-01-01), Wong et al.
patent: 7338953 (2008-03-01), Wong et al.
patent: 2008/0275131 (2008-11-01), Le Bourdonnec
patent: 2009/0005722 (2009-01-01), Jennlngs-Spring
patent: 2009/0233957 (2009-09-01), Le Bourdonnec
patent: 2009/0233958 (2009-09-01), Le Bourdonnec
patent: WO 01/62341 (2001-08-01), None
patent: WO 2006/000903 (2006-01-01), None
patent: WO 2007/041258 (2007-04-01), None
patent: WO 2009/105507 (2009-08-01), None
Sindrup et al. in Basic and Clinical Pharmacology & Toxicology 2005, 96, 399-409.
van Bemmel et al. in Neuropsychobiology 1999, 40:107-114.
Amitriptyline Injection (www.goldbamboo.com/topic-t4747.html.).
Nagakura et al. in the Journal of Pharmacology and Experimental Therapeutics 306:490-497, 2003.
Amitriptyline Injection (www.goldbamboo.com/topic-t4747.html.) (published online Jun. 1, 2005).
Aragona et al., 2005, “Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder,”European Journal of Pain9(1):33-38.
Atkinson et al., 1999, “Effects of Noradrenergic and Serotonergic Antidepressants on Chronic Low Back Pain Intensity,”Pain83(2):137-145.
van Bemmel et al., 1999, “The Acute Effects of the Noradrenaline Reuptake Inhibitor Org 4428 on EEG Sleep in Healthy Volunteers,”Neuropsychobiology40: 107-114.
Bomholt et al., 2005, “Antinociceptive Effects of the Antidepressants Amitriptyline, Duloxetine, Mirtazapine and Citalopram in Animal Models of Acute, Persistent and Neuropathic Pain,”Neuropharmacology48(2):252-263.
Bymaster et al., 2005, “The Dual Transporter Inhibitor Duloxetine: A Review of Its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression,”Current Pharmaceutical Design11:1475-1493.
Canavero et al., 2002, “Reboxetine for Central Pain: A Single-Blind Prospective Study,”Clinical Neuropharmacology25(4):238-239.
Canavero et al., 2004, “Norepinephrine and Pain,”Pain107(3):279.
Claghorn et al., 1996, “Recent Developments in Antidepressant Agents,”Progress in Drug Research46:243-262.
Collins et al., 2000, “Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia: A Quantitative Systematic Review,”Journal of Pain an Symptom Management20(6):449-458.
Crowell et al., 2004, “Antidepressants in the Treatment of Irritable Bowel Syndrome and Visceral Pain Syndromes,”Current Opinion in Investigational Drugs5(7):736-742.
Demling, 1996, “Tetrazyklishe Antidepressiva: Pharmakologisch-klinische Aspekte unde Neuentwicklungen,”Nevernheilkunde15:92-100 (English language abstract).
Freynhagen et al., 2006, “Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats,”Brain Research Bulletin69:168-173.
Goldstein et al., 2005, “Duloxetine vs. Placebo in Patients with Painful Diabetic Neuropathy,”Pain116:109-118.
Hashimoto et al., 1996, “Serotonin Reuptake Inhibitors Reduce Conditioned Fear Stress Induced Freezing Behavior in Rats,”Psychopharmacology123:182-186.
International Search Report and the Written Opinion, Notification of Transmittal of, of the International Searching Authority or the Declaration dated May 14, 2009 for Application No. PCT/US2009/34461.
Iyengar et al., 2004, “Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in Rats,”The Journal of Pharmacology and Experimental Therapeutics311(2): 576-584.
Jones et al., 2005, “Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents,”The Journal of Pharmacology and Experimental Therapeutics312(2):726-732.
Jones et al., 2006, “Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition,”Neuropharmacology51(7-8):1172-1180.
Krell et al., 2005, “Evaluation of Reboxetine, A Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back Pain,”Psychosomatics46(5):379-384.
Leventhal et al., 2007, “Differential and Synergistic Effects of Selective Norepinephrine and Serotonin Reuptake Inhibitors in Rodent Models of Pain,”The Journal of Pharmacology and Experimental Therapeutics320(3):1178-1185.
Mahaney et al., 2008—published on the Web Jun. 17, 2008, “Structure-Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors,”J. Med. Chem. 51(13): 4038-4049.
Max et al., 1992, “Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy,”The New England Journal of Medicine326(19):1250-1256.
Muth-Selbach et al., 2009, “Racemic intrathecal mirtazapine but not its enantiomers acts anti-neuropathic after chronic constriction injury in rats,”Brain Research Bulletin79:63-68.
Obata et al., 2005, “Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats,”Pain113(3):271-276.
Paanakker et al., 1998, “Validation of an LC-MS Assay for the Quantification of the Enantiomers of Org 4428 In Human Plasma,”J. Pharm. Biomed. Anal. 16:981-989.
Pederson et al., 2005, “Anti-nociception is Selectively Enhanced by Parallel Inhibition of Multiple Subtypes of Monoamine Transporters in Rat Models of Persistent and Neuropathic Pain,”Psychopharmacology182(4):551-561.
Schreiber et al., 1998, “Interaction between the tetracyclic antidepressant mianserin HC1 and opioid receptors,”European Neuropsychopharmacology8:297-302.
Schreiber et al., 2009, “The antinociceptive properties of reboxetine in acute pain,”European Neuropsychopharmacology, 19(10): 735-739.
Sindrup et al., 1999, “Efficacy of Pharmacological Treatments of Neuropathic Pain: An Update and Effect Related to Mechanism of Drug Action,”Pain83:389-400.
Sperling et al., 1997, “New Tetracyclic Antidepressants,”Drugs of Today33(2):95-102.
Tatsumi et al., 1997, “Pharmacological profile of antidepressants and related compounds at human monoamine transporters,”European Journal of Pharmacology340:249-258.
Wernicke, 2007, “Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine,”Current Drug Therapy2(2): 161-167.
Wikström et al., 2002, “Synthesis and Pharmacological Testing of 1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methyldibezo[c,f,]Apyrazinol[1,2-a]azepin and Its Enantiomers in Comparison with the Two Antidepressants Mianserin and Mirtazapine,”Journal of Medicinal Chemistry45:3280-3285.
Yalcin et al., 2009, “β2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain,”Neurobiology of Disease33(3):386-394.
Zhang, 2009, “1- or 3-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors,”J. Med Chem. 52(18):5703-5711.
ORG-4428: CNS Testing Phase III (Internal Report), 5 pages, Feb. 19, 1999.
Pharmacological Data for ORG-2448 (Internal Report), 4 pages, Feb. 19, 1999.
Investigation's Brochure for ORG-4428 Capsules, 3 pages, Feb. 19, 1999.
Dolle Roland E.
Le Bourdonnec Bertrand
Adolor Corporation
Dechert LLP
Fetterolf Brandon J
Heyer Dennis
LandOfFree
Beloxepin and analogs for the treatment of pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beloxepin and analogs for the treatment of pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beloxepin and analogs for the treatment of pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252432